Preparation and purification of novel phosphatidyl prodrug and performance modulation of phosphatidyl nanoprodrug

Abstract

Background

A novel phosphatidyl nanoprodrug system can be selectively released parent drugs in cancer cells, triggered by the local overexpression of phospholipase D (PLD). This system significantly reduces the intrinsic disadvantages of conventional chemotherapeutic drugs. However, the separation and purification processes of phosphatidyl prodrug, the precursor of phosphatidyl nanoprodrug, have not been established, and the preparation of nanocrystals with good stability and tumor-targeting capability is still challenging.

Results

In this study, we established a successive elution procedure for the phosphatidyl prodrug—phosphatidyl mitoxantrone (PMA), using an initial ten-bed volume of chloroform/methanol/glacial acetic acid/water (26/10/0.8/0.7) (v/v/v/v) followed by a five-bed volume (26/10/0.8/3), with which purity rates of 96.93% and overall yields of 50.35% of PMA were obtained. Moreover, to reduce the intrinsic disadvantages of conventional chemotherapeutic drugs, phosphatidyl nanoprodrug—PMA nanoprodrug (NP@PMA)—was prepared. To enhance their stability, nanoparticles were modified with polyethylene glycol (PEG). We found that nanoprodrugs modified by PEG (NP@PEG–PMA) were stably present in RPMI-1640 medium containing 10% FBS, compared with unmodified nanoprodrug (NP@PMA). To enhance active tumor-targeting efficiency, we modified nanoparticles with an arginine-glycine-aspartic acid (RGD) peptide (NP@RGD–PEG–PMA). In vitro cytotoxicity assays showed that, compared with the cytotoxicity of NP@PEG–PMA against tumor cells, that of NP@RGD–PEG–PMA was enhanced. Thus, RGD modification may serve to enhance the active tumor-targeting efficiency of a nanoprodrug, thereby increasing its cytotoxicity.

Conclusions

A process for the preparation and purification of novel phosphatidyl prodrugs was successfully established, and the nanoprodrug was modified using PEG for enhanced nanoparticle stability, and using RGD peptide for enhanced active tumor-targeting efficiency. These procedures offer considerable potential in the development of functional antitumor prodrugs.

Keywords

Phosphatidyl prodrug / Purification / Gradient elution / Silica gel column chromatography / PEGylation / RGD modification

References

[1] Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res, 2005, 44: 68-97.

[2] Antignani A, Fitzgerald D. Immunotoxins: the role of the toxin. Toxins, 2013, 5: 1486-1502.

[3] Bildstein L, Dubernet C, Couvreur P. Prodrug-based intracellular delivery of anticancer agents. Adv Drug Deliv Rev, 2011, 63: 3-23.

[4] Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharm., 2017, 9: 12.

[5] Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Release, 2010, 148: 135-146.

[6] Dos Santos N, Allen C, Doppen A-M, Anantha M, Cox KAK, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta Biomembr, 2007, 1768: 1367-1377.

[7] Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliver Rev, 2011, 63: 136-151.

[8] Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano, 2009, 3: 16-20.

[9] Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. Drugs, 1991, 41: 400-449.

[10] Hirche F, Koch MHJ, König S, Wadewitz T, Ulbrich-Hofmann R. The influence of organic solvents on phospholipid transformations by phospholipase D in emulsion systems. Enzyme Microb Technol, 1997, 20: 453-461.

[11] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol, 2010, 7: 653-664.

[12] Jiang Z, Guan J, Qian J, Zhan C. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomater Sci, 2019, 7(2): 461-471.

[13] Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol, 1990, 143: 381-385.

[14] Ku SH, Ryu J, Hong SK, Lee H, Park CB. General functionalization route for cell adhesion on non-wetting surfaces. Biomaterials, 2010, 31: 2535-2541.

[15] Liu B-Y, Yang X-L, Xing X, Li J, Liu Y-H, Wang N, Yu X-Q. Trackable water-soluble prodrug micelles capable of rapid mitochondrial-targeting and alkaline pH-responsive drug release for highly improved anticancer efficacy. ACS Macro Lett, 2019, 8: 719-723.

[16] Luo C-Q, Zhou Y-X, Zhou T-J, Xing L, Cui P-F, Sun M, Jin L, Lu N, Jiang H-L. Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy. J. Control Release, 2018, 274: 56-68.

[17] Lutz FT, Kianga S. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Curr Pharm Design, 2011, 17: 3527-3547.

[18] Mahmudul H, Safaet A, Saikat Kumar P. Antibody-drug conjugates: a review on the epitome of targeted anti-cancer therapy. Curr Clin Pharmacol., 2018, 13: 236-251.

[19] Majzoub RN, Chan C-L, Ewert KK, Silva BFB, Liang KS, Jacovetty EL, Carragher B, Potter CS, Safinya CR. Uptake and transfection efficiency of PEGylated cationic liposome–DNA complexes with and without RGD-tagging. Biomaterials, 2014, 35: 4996-5005.

[20] Melwita E, Tsigie YA, Ismadji S, Ju Y-H. Purification of azadirachtin via silica gel column chromatography. J Liq Chromatogr Relat Technol, 2011, 34: 2462-2472.

[21] Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol^®). J. Control Release, 2002, 80: 129-144.

[22] Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater, 2013, 12: 991.

[23] Nik ME, Malaekeh-Nikouei B, Amin M, Hatamipour M, Teymouri M, Sadeghnia HR, Iranshahi M, Jaafari MR. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal doxorubicin in mouse colon carcinoma. Sci Rep, 2019, 9: 9527.

[24] Oliyai R. Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv Drug Deliver Rev, 1996, 19: 275-286.

[25] Petersen MA, Hillmyer MA, Kokkoli E. Bioresorbable polymersomes for targeted delivery of cisplatin. Bioconjug Chem, 2013, 24: 533-543.

[26] Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis, 2015, 243: 449-461.

[27] Sangrà M, Estelrich J, Sabaté R, Espargaró A, Busquets MA. Evidence of protein adsorption in pegylated liposomes: influence of liposomal decoration. Nanomaterials, 2017, 7: 37.

[28] Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Therapeut, 2013, 138: 452-469.

[29] Shi K, Li J, Cao Z, Yang P, Qiu Y, Yang B, Wang Y, Long Y, Liu Y, Zhang Q, Qian J, Zhang Z, Gao H, He Q. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma. J. Control Release, 2015, 217: 138-150.

[30] Tao X, Jia N, Cheng N, Ren Y, Cao X, Liu M, Wei D, Wang F-Q. Design and evaluation of a phospholipase D based drug delivery strategy of novel phosphatidyl-prodrug. Biomaterials, 2017, 131: 1-14.

[31] Wakaskar RR. Promising effects of nanomedicine in cancer drug delivery. J Drug Target, 2018, 26: 319-324.

[32] Wang Q, Zhang X, Liao H, Sun Y, Ding L, Teng Y, Zhu W-H, Zhang Z, Duan Y. Multifunctional shell-core nanoparticles for treatment of multidrug resistance hepatocellular carcinoma. Adv Funct Mater, 2018, 28: 1706124.

[33] Wu S, Wang Y, Gong G, Li F, Ren H, Liu Y. Adsorption and desorption properties of macroporous resins for flavonoids from the extract of Chinese wolfberry (Lycium barbarum L.). Food Bioprod Process, 2015, 93: 148-155.

[34] Xiang B, Dong D-W, Shi N-Q, Gao W, Yang Z-Z, Cui Y, Cao D-Y, Qi X-R. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials, 2013, 34: 6976-6991.

[35] Xiao Z, Levy-Nissenbaum E, Alexis F, Lupták A, Teply BA, Chan JM, Shi J, Digga E, Cheng J, Langer R, Farokhzad OC. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano, 2012, 6: 696-704.

[36] Yang Y, Pan D, Luo K, Li L, Gu Z. Biodegradable and amphiphilic block copolymer–doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Biomaterials, 2013, 34: 8430-8443.

[37] Yang Y, Yang Y, Xie X, Cai X, Zhang H, Gong W, Wang Z, Mei X. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide–doxorubicin conjugate for tumor-specific therapy. Biomaterials, 2014, 35: 4368-4381.

[38] Zhang K, Wang X, Huang J, Liu Y. Purification of l-alpha glycerylphosphorylcholine by column chromatography. J Chromatogr A, 2012, 1220: 108-114.

[39] Zheng X, Wu F, Lin X, Shen L, Feng Y. Developments in drug delivery of bioactive alkaloids derived from traditional Chinese medicine. Drug Deliv, 2018, 25: 398-416.

[40] Zhou H, Xu H, Li X, Lv Y, Ma T, Guo S, Huang Z, Wang X, Xu P. Dual targeting hyaluronic acid—RGD mesoporous silica coated gold nanorods for chemo-photothermal cancer therapy. Mater Sci Eng C Mater, 2017, 81: 261-270.

[41] Zhou C, Xie X, Yang H, Zhang S, Li Y, Kuang C, Fu S, Cui L, Liang M, Gao C, Yang Y, Gao C, Yang C. Novel class of ultrasound-triggerable drug delivery systems for the improved treatment of tumors. Mol Pharm, 2019, 16: 2956-2965.

Funding

National Natural Science Foundation of China(No.81603056)